Apnimed's experimental drug reduced breathing interruptions by nearly 46.8% in clinical trials, offering a potential ...

In today’s Health Alert, obstructive sleep apnea may soon be treated with a simple, once-a-day pill. This first-in-class oral drug has shown real promise in a large phase 3 clinical trial.

The first oral pill for obstructive sleep apnea (OSA) could be around the corner after pharmaceutical company Apnimed Inc.

Pharmaceutical company Apnimed says it's getting positive results from the clinical trials for an oral pill that could treat ...

The new pill, called AD109, is a combination of atomoxetine and aroxybutynin, two drugs that tell your brain to keep the ...

Apnimed, a pharmaceutical company developing oral therapies for obstructive sleep apnea (OSA) and related conditions, announced positive topline results from its second pivotal Phase 3 trial of AD109 ...

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...

Topline results from a second phase 3 trial of AD109-an investigational oral therapy combining aroxybutynin and ...

“Sleep apnea mouthguards (Oral Appliance Therapy) fit over the teeth and gums and keeps the airway patent resulting in improved sleep quality and other outcomes. They are FDA approved devices with ...

The sleep apnea detection feature that Apple's most recent Apple Watch models offer has expanded to several more countries in ...

Central Sleep Apnea This type of apnea occurs when something goes awry with the brain’s normal signaling to muscles that control breathing in the body, causing breathing to repeatedly stop or ...

Sleep apnea can cause a range of symptoms, from snoring to fatigue, making it tough for the average person to pin down the signs or even to realize that they have a health issue.